High baseline serum thymidine kinase 1 level predicts unfavorable outcome in patients with follicular lymphoma

Leukemia and Lymphoma

Volumn 53, Issue 7, 2012, Pages 1306-1310

  Procházka, Vít ^a   Faber, Edgar ^a   Raida, Luděk ^a   Langová, Kateřina ^a   Indrák, Karel ^a   Papajík, Tomáš ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

autologous transplant; chemotherapy; FLIPI; Follicular lymphoma; prognosis; thymidine kinase

Indexed keywords

ALPHA INTERFERON; BETA 2 MICROGLOBULIN; BLEOMYCIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; IBRITUMOMAB TIUXETAN; IFOSFAMIDE; KI 67 ANTIGEN; LACTATE DEHYDROGENASE; MELPHALAN; MESNA; METHOTREXATE; MITOXANTRONE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; THYMIDINE KINASE 1; VINCRISTINE;

ADD ON THERAPY; ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ASSESSMENT; FEMALE; FOLLICULAR LYMPHOMA; FOLLICULAR LYMPHOMA INTERNATIONAL PROGNOSTIC INDEX SCORE; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RISK ASSESSMENT; SCORING SYSTEM;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BETA 2-MICROGLOBULIN; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; L-LACTATE DEHYDROGENASE; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; OUTCOME ASSESSMENT (HEALTH CARE); PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; STEM CELL TRANSPLANTATION; THYMIDINE KINASE; TRANSPLANTATION, AUTOLOGOUS;

EID: 84862742606     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.654339     Document Type: Article

References (27)

1. Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001.Blood 2006;107:265-276. (Pubitemid 43053551)
2. Trneny M, Vasova I, Pytlik R, et al. The non-Hodgkin's lymphoma subtypes distribution and survival in Czech Republic. Klin Onkol 2007;20:341-348.
3. Swenson WT, Wooldridge JE, Lynch CF, et al. Improved survival of follicular lymphoma patients in the United States. J Clin Oncol 2005;23:5019-5026. (Pubitemid 46224008)
4. Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004;104:1258-1265. (Pubitemid 39166497)
5. van de Schans SA, Steyerberg EW, Nijziel MR, et al. Validation, revision and extension of the Follicular Lymphoma International Prognostic Index (FLIPI) in a population-based setting. Ann Oncol 2009;20:1697-1702.
6. Buske C, Hoster E, Dreyling M, et al. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood 2006;108:1504-1508. (Pubitemid 44321768)
7. Montoto S, Lopez-Guillermo A, Altes A, et al. Predictive value of Follicular Lymphoma International Prognostic Index (FLIPI) in patients with follicular lymphoma at first progression. Ann Oncol 2004;15:1484-1489. (Pubitemid 39409738)
8. Federico M, Bellei M, Marcheselli L, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 2009;27:4555-4562.
9. Prochazka V, Papajik T, Jarosova M, et al. Prognostic factors in follicular lymphoma in the rituximab era: how to identify a high-risk patient? Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2011;155:99-108.
10. Gronowitz JS, Kallander CF. Optimized assay for thymidine kinase and its application to the detection of antibodies against herpes simplex virus type 1- and 2-induced thymidine kinase. Infect Immun 1980;29:425-434. (Pubitemid 10040153)
11. Hagberg H, Gronowitz S, Killander A, et al. Serum thymidine kinase in acute leukaemia. Br J Cancer 1984;49:537-540. (Pubitemid 14125263)
12. Gronowitz JS, Kallander FR, Diderholm H, et al. Application of an in vitro assay for serum thymidine kinase: results on viral disease and malignancies in humans. Int J Cancer 1984;33:5-12. (Pubitemid 14223226)
13. Li Z, Wang Y, He J, et al. Serological thymidine kinase 1 is a prognostic factor in oesophageal, cardial and lung carcinomas. Eur J Cancer Prev 2010;19:313-318.
14. Nisman B, Allweis T, Kaduri L, et al. Serum thymidine kinase 1 activity in breast cancer. Cancer Biomark 2010;7:65-72.
15. Huang S, Lin J, Guo N, et al. Elevated serum thymidine kinase 1 predicts risk of pre/early cancerous progression. Asian Pac J Cancer Prev 2011;12:497-505.
16. Aufderklamm S, Todenhoefer T, Gakis G, et al. Thymidine kinase and cancer monitoring. Cancer Lett 2012;316:6-10.
17. Suzuki K, Terui Y, Nakano K, et al. High thymidine kinase activity is a strong predictive factor for poor prognosis in PTCLs treated by CHOP. Leuk Lymphoma 2011 Oct 13. [Epub ahead of print]
18. Pan ZL, Ji XY, Shi YM, et al. Serum thymidine kinase 1 concentration as a prognostic factor of chemotherapy-treated non-Hodgkin's lymphoma patients. J Cancer Res Clin Oncol 2010;136:1193-1199.
19. Konoplev SN, Fritsche HA, O'Brien S, et al. High serum thymidine kinase 1 level predicts poorer survival in patients with chronic lymphocytic leukemia. Am J Clin Pathol 2010;134:472-477.
20. Ohrvik A, Lindh M, Einarsson R, et al. Sensitive nonradiometric method for determining thymidine kinase 1 activity. Clin Chem 2004;50:1597-1606. (Pubitemid 39121228)
21. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues, Vol. 2. Lyon: IARC Press; 2008.
22. Decaudin D, Lepage E, Brousse N, et al. Low-grade stage III-IV follicular lymphoma: multivariate analysis of prognostic factors in 484 patients - a study of the groupe d'Etude des lymphomes de l'Adulte. J Clin Oncol 1999;17:2499-2505. (Pubitemid 29368251)
23. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328:1002-1006. (Pubitemid 23095683)
24. Federico M, Clo V, Brugiatelli M, et al. Efficacy of two different ProMACE-CytaBOM derived regimens in advanced aggressive non-Hodgkin's lymphoma. Final report of a multicenter trial conducted by GISL. Haematologica 1998;83:800-811. (Pubitemid 28496169)
25. Prochazka V, Faber E, Raida, et al. Prolonged survival of patients with peripheral T-cell lymphoma after first-line intensive sequential chemotherapy with autologous stem cell transplantation. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2009;153:63-66.
26. Colombat P, Biron P, Laporte JP, et al. BEAM protocol and autologous bone marrow transplantation in first chemosensitive relapse of non-Hodgkin's lymphomas. Eur J Cancer 1990;26:858. (Pubitemid 20328575)
27. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.